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SYSTEMS AND METHODS FOR DIAGNOSIS 
AND MONITORING OF 
BACTERIA-RELATED CONDITIONS 
RELATED APPLICATIONS 
This application claims priority from US. Provisional 
Application Ser. No. 60/971 ,228 ?led Sep. 10, 2007, Which is 
incorporated herein by this reference. 
GOVERNMENT INTEREST 
Subject matter described herein Was made With US. Gov 
ernment support under Grant Number CHE-0416553 
aWarded by the National Science Foundation (NSF). The 
government has certain rights in the described subject matter. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to diagnos 
ing and monitoring conditions of interest. In particular, the 
presently-disclosed subject matter relates to diagnosing and 
monitoring bacteria-related conditions. 
INTRODUCTION AND GENERAL 
CONSIDERATIONS 
Bacterial quorum sensing (QS) is a cell-to-cell communi 
cation phenomenon Whereby bacterial cells produce signal 
ing molecules intracellularly, Which are released into the 
environment. Although these signaling molecules diffuse in 
and out of cells, the concentration of the signaling molecules 
in the environment re?ects the population of bacteria that are 
present in a given environment or, in other Words, the cell 
density of the bacterial population. To date, a variety of sig 
naling molecules, termed quorum sensing molecules (QSM), 
have been identi?ed, including N-acyl homoserine lactones 
(AHLs), Which are used by many gram-negative bacteria; and 
oligopeptides, Which are used by many gram-positive bacte 
ria. In addition, a family of autoinducers, knoWn as AI-2, has 
been identi?ed and is produced by both gram-positive and 
gram-negative bacteria. [1] The quorum sensing process 
regulates the gene expression necessary for many bacterial 
activities including bio?lm formation, light production, for 
mation of virulence determinants, transfer of carcinogenic Ti 
plasmid, and several others. [1] The mechanism by Which 
bacteria cause disease involves a delay in the expression of 
the genes responsible for the formation of virulence factors 
until the quorum sensing process produces a large enough 
bacterial population that it is capable of overWhelming the 
host defense system. [3] 
Further, it is appreciated that once the concentration of the 
signaling molecules reaches a speci?c level, the bacteria can 
monitor population density and alter their group behavior. [3] 
In this regard, the QSMs bind to their sensor/regulatory pro 
tein, resulting in the activation of quorum sensing-dependent 
virulence/target genes. 
Bacteria are thought to play an important role in many 
disorders ranging from infections to chronic in?ammation. 
Among those, there are numerous reports in both animal 
models and humans that bacteria play a signi?cant role in 
gastrointestinal (GI) diseases, such as in?ammatory boWel 
disease (IBD). [4] In?ammatory boWel disease, Which 
includes Crohn’s disease (CD) and ulcerative colitis (UC), is 
a chronic gastrointestinal in?ammatory condition With 
unknown etiology. To support the involvement of bacteria in 
these diseases are the identi?cation of serologic markers 
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against microbial antigens and the successful use of antibiotic 
therapy in subjects With Crohn’ s disease, as Well as the obser 
vation that colitis cannot be induced in animals Without bac 
terial ?ora. [5] Additionally, there is evidence for the involve 
ment of quorum sensing in the pathogenesis of several 
diseases. For instance, bacteria-producing signaling mol 
ecules have been shoWn to be responsible for bio?lm forma 
tion in the lungs. [6] These signaling molecules have been 
detected in the sputum of subjects With cystic ?brosis [7] and 
have been suspected to be involved in several illnesses of the 
GI Tract. [5,8,9] Interestingly, signaling molecules have been 
shoWn to induce several chemokines and cytokines respon 
sible for in?ammation, and inhibit others that are immuno 
suppressive in nature, in both in vitro and in vivo experiments. 
[10] 
To date, there is a lack of quick and non- or minimally 
invasive methods for the monitoring of acute and chronic 
bacteria-related conditions. Crohn’s disease, for example, 
usually occurs in the loWer part of the small intestine, i.e., the 
ileum, but it can affect any part of the digestive tract, from the 
mouth to the anus. Crohn’s disease exacerbation is usually 
diagnosed With a combination of clinical symptoms and 
blood tests for non-speci?c in?ammatory markers, and in 
some instances an endoscopy. Methods and systems alloWing 
for the non-invasive monitoring of subjects With Crohn’s 
disease and other bacteria-related conditions Would alloW for 
early identi?cation of exacerbations and, consequently, for 
therapy administration before the onset of a “?are-up,” 
thereby decreasing the hardship that such conditions cause to 
the subjects. Accordingly, there remains a need in the art for 
systems and methods for diagnosing and monitoring bacteria 
related conditions. 
SUMMARY 
The presently-disclosed subject matter meets some or all of 
the above-identi?ed needs, as Will become evident to those of 
ordinary skill in the art after a study of information provided 
in this document. This Summary describes several embodi 
ments of the presently-disclosed subject matter, and in many 
cases lists variations and permutations of these embodiments. 
This Summary is merely exemplary of the numerous and 
varied embodiments. Mention of one or more representative 
features of a given embodiment is likeWise exemplary. Such 
an embodiment can typically exist With or Without the 
feature(s) mentioned; likeWise, those features can be applied 
to other embodiments of the presently-disclosed subject mat 
ter, Whether listed in this Summary or not. To avoid excessive 
repetition, this Summary does not list or suggest all possible 
combinations of such features. 
The presently-disclosed subject matter provides, in some 
embodiments, a method of diagnosing a bacteria-related con 
dition in a subject. In some embodiments, the method com 
prises providing a biological sample from a subject; deter 
mining an amount in the sample of at least one quorum 
sensing molecule (QSM); and comparing the amount of the at 
least one QSM in the sample, if present, to a control level of 
the at least one QSM. If there is a measurable difference in the 
amount of the at least one QSM in the sample as compared to 
the control level, the subject can then be diagnosed as having 
the bacteria-related condition of interest or a risk thereof. 
In some embodiments, the QSM is an N-acyl homoserine 
lactone (AHL) or an autoinducer-2 (AI-2). In some embodi 
ments, the AHL is selected from: N-butyryl homoserine lac 
tone (C4-HSL), N-hexanoyl homoserine lactone (C6-HSL), 
N-(3 -oxo)-hexanoyl homoserine lactone (3 -oxo-C6-HSL), 
N-octanoyl homoserine lactone (C8-HSL), N-(3 -oxo)-oc 
US 8,663,927 B2 
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tanoyl homoserine lactone (3-oxo-C8-HSL), N-decanoyl 
homoserine lactone (ClO-HSL), N-dodecanoyl homoserine 
lactone (Cl2-HSL), N-(3-oxo)-dodecanoyl homoserine lac 
tone (3-oxo -C l 2-HSL), N-tetradecanoyl homoserine lactone 
(Cl4-HSL), and combinations thereof. 
In some embodiments, determining the amount in the 
sample of the at least one QSM comprises determining the 
amount in the sample of the at least one QSM using a cell 
sensing system. In some embodiments, the cell sensing sys 
tem comprises a bacterial cell; a regulatory protein Within the 
bacterial cell for binding at least one QSM; and, a reporter 
molecule Within the bacterial cell for detecting binding of the 
QSM to the regulatory protein, Where the reporter molecule 
generates a detectable signal upon binding of the QSM to the 
regulatory protein. In some embodiments, the cell sensing 
system further comprises a substrate supporting the bacterial 
cell and a signal reader for detecting the signal generated by 
the reporter molecule. In some embodiments, the bacterial 
cell comprises a heterologous reporter gene cassette that 
comprises a promoter operatively linked to a nucleotide 
sequence encoding the reporter molecule. In some embodi 
ments, the reporter gene cassette is luxCDABE. In some 
embodiments, the reporter gene cassette is luxCDABE, the 
promoter is PM”, and the regulatory peptide is RhlR. In some 
embodiments, the reporter gene cassette is luxCDABE, and 
the promoter and regulatory peptide are PMS, and LasR, 
respectively. 
Further, in some embodiments of the presently-disclosed 
subject matter, the QSM-regulatory complex has binding 
a?inity for the promoter such that the regulatory peptide 
binds the promoter and activates expression of the reporter 
molecule to thereby generate a detectable signal. In some 
embodiments, the detectable signal is bioluminescence. In 
some embodiments, an amount of the detectable signal cor 
relates to a concentration of the QSM. 
Still further provided, in some embodiments of the pres 
ently-disclosed methods, the determined amount of the at 
least one QSM can be used to select or modify a treatment for 
the bacteria-related condition of interest. In some embodi 
ments, a method for determining Whether to initiate or con 
tinue prophylaxis or treatment of a bacteria-related condition 
of interest in a subject is provided. In some embodiments, the 
method comprises providing a series of biological samples 
over a time period from the subject; analyZing the series of 
biological samples to determine an amount in each of the 
biological samples of the at least one QSM; and, comparing 
any measurable change in the amounts of the at least one 
QSM in each of the biological samples to thereby determine 
Whether to initiate or continue the prophylaxis or treatment of 
the bacteria-related condition of interest. 
In some embodiments of the methods of the presently 
disclosed subject matter, the subject is human. In some 
embodiments, a biological sample is provided from the sub 
ject. In some embodiments, the biological sample is a saliva 
sample, and, in some embodiments, the biological sample, is 
a stool sample. 
In some embodiments, the bacteria-related condition is a 
bacterial infection. In some embodiments, the bacteria-re 
lated condition is an in?ammation, such as, in some embodi 
ments, a chronic in?ammation. In some embodiments, the 
bacteria-related condition of interest is a condition of the 
gastro-intestinal tract. In some embodiments, the condition is 
an in?ammatory boWel disease (IBD), including, in some 
embodiments, Crohn’s disease and ulcerative colitis. 
Still further provided, in some embodiments of the pres 
ently-disclosed subject matter, is a kit for diagnosing a bac 
teria-related condition of interest in a subject. In some 
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embodiments, the kit comprises a cell sensing system in 
accordance With the presently-disclosed subject matter and 
instructions for using the kit. 
Accordingly, it is an object of the presently-disclosed sub 
ject matter to provide systems, methods, and kits for diagnos 
ing and monitoring a bacteria-related condition of interest in 
a subject. This object is achieved in Whole or in part by the 
presently-disclosed subject matter. 
An object of the presently-disclosed subject matter having 
been stated hereinabove, and Which is achieved in Whole or in 
part by the presently-disclosed subject matter, other objects 
and advantages Will become evident to those of ordinary skill 
in the art after a study of the folloWing description of the 
presently-disclosed subject matter, Figures, and non-limiting 
Examples. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 includes the chemical structures of N-acyl 
homoserine lactones (AHLs) produced by different bacterial 
species, and the respective LuxI homologues responsible for 
AHL synthesis in each bacterial species. 
FIG. 2 contains a schematic representation of AHL-depen 
dent regulation of quorum sensing in LuxR/LuxI-type sys 
tems (FIG. 2A) and a schematic representation of the plas 
mids pSBl075 and pSB406, Which contain lasR and rhlR 
regulatory genes, respectively, fused With the reporter gene 
cassette luxCDABE. 
FIG. 3 includes calibration curves for exemplary cell sens 
ing systems employing plasmid pSB406 (left panel) and pSB 
1075 (right panel), Where bacterial cells Were incubated With 
different N-acyl-DL-homoserine lactones, namely, N-hex 
anoyl-DL-homoserine lactone (upWard-pointing triangle), 
N-butyryl-DL-homoserine lactone (square), N-octanoyl-DL 
homoserine lactone (circle), N-dodecanoyl-DL-homoserine 
lactone (diamond), and N-tetradecanoyl-DL-homoserine lac 
tone (doWnWard-pointing triangle), and Where the signals 
have been corrected With respect to a blank, and Where data 
shoWn are the averageione standard deviation. 
FIG. 4 includes an evaluation of saliva matrix effects using 
an exemplary biosensing system employing plasmid pSB406 
and N-hexanoyl-DL-homo serine lactone as an analyte, Where 
the dose-response curve is achieved by analyte standard addi 
tion to a pool of saliva samples from four healthy subjects 
(upWard-pointing triangles) and the reference calibration 
curve (square) is obtained during the same analytical run, and 
Where the signals have been corrected With respect to the 
blank, and Where data shoWn are the averageione standard 
deviation. 
FIG. 5 is a graph depicting levels of short and long chain 
AHLs and fecal lactoferrin detected in boWel secretion 
samples from in?ammatory boWel disease (IBD) subjects. 
FIG. 6 is a graph shoWing a comparison betWeen long chain 
AHL levels in diseased and control subjects. 
FIG. 7 contains graphs depicting levels of short and long 
chainAHLs detected in saliva samples from IBD subjects and 
control subjects. 
FIG. 8 is a graph depicting levels of short and long chain 
AHLs detected in stool samples from infants admitted to a 
Neonatal Intensive Care Unit (NICU). 
FIG. 9 includes a diagram of a microcentrifuge compact 
disc (CD) micro?uidics platform (FIG. 9A) and a diagram of 
a micro?uidics structure (FIG. 9B) of the CD micro?uidics 
platform containing small Wells for the addition of sensing 
bacterial cells and samples, and a detection chamber linked to 
the Wells by a mixing channel. 
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FIG. 10 is a schematic representation of an exemplary CD 
micro?uidics platform attached to a rotor, Where biolumines 
cent reactions in the micro?uidic structures are detected by a 
photomultiplier tube (PMT) attached to a transducer that 
generates a readable signal. 
FIG. 11 is a graph depicting results of a time-course study 
using N-hexanoyl-DL-homoserine lactone in an exemplary 
CD micro?uidics platform. 
FIG. 12 is a graph depicting the reproducibility of an exem 
plary CD micro?uidics platform for detecting quorum sens 
ing molecules (QSMs). 
FIG. 13 is a graph depicting the ability of an exemplary CD 
micro?uidics platform to detect QSMs in a biological sample. 
FIG. 14 is a calibration curve obtained using various con 
centrations of autoinducer-2 (AI-2). 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently 
disclosed subject matter are set forth in this document. Modi 
?cations to embodiments described in this document, and 
other embodiments, Will be evident to those of ordinary skill 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the speci?c details of the described exemplary 
embodiments, is provided primarily for cleamess of under 
standing and no unnecessary limitations are to be understood 
therefrom. In case of con?ict, the speci?cation of this docu 
ment, including de?nitions, Will control. 
While the folloWing terms are believed to be Well under 
stood by one of ordinary skill in the art, the following de?ni 
tions are set forth to facilitate explanation of the presently 
disclosed subject matter. 
Unless de?ned otherWise, all technical and scienti?c terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to Which the presently 
disclosed subject matter belongs. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently 
disclosed subject matter, representative methods, devices, 
and materials are noW described. 
FolloWing long-standing patent laW convention, the terms 
“a”, “an”, and “the” refer to “one or more” When used in this 
application, including the claims. Thus, for example, refer 
ence to “a cell” includes a plurality of such cells, and so forth. 
Unless otherWise indicated, all numbers expressing quan 
tities of ingredients, properties such as reaction conditions, 
and so forth used in the speci?cation and claims are to be 
understood as being modi?ed in all instances by the term 
“about.” Accordingly, unless indicated to the contrary, the 
numerical parameters set forth in this speci?cation and claims 
are approximations that can vary depending upon the desired 
properties sought to be obtained by the presently-disclosed 
subject matter. 
As used herein, the term “about,” When referring to a value 
or to an amount of mass, Weight, time, volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments 120%, in some embodiments 110%, in some 
embodiments 15%, in some embodiments 11%, in some 
embodiments 10.5%, and in some embodiments 10.1% from 
the speci?ed amount, as such variations are appropriate to 
perform the disclosed method. 
Bacteria communicate With neighboring bacterial cells by 
producing signaling molecules intracellularly that are 
released into the environment, and the concentration of these 
signaling molecules re?ects the cell density of the bacterial 
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population. Once the concentration of the signaling mol 
ecules reaches a speci?c level, the bacteria can monitor their 
population density and alter their group behavior, including, 
but not limited to, altering and controlling the expression of 
certain specialiZed genes depending on the siZe of the bacte 
rial population. This phenomenon is termed “quorum sens 
ing” and is a process Whereby the expression of genes neces 
sary for many bacterial activities, such as bio?lm formation, 
light production, formation of virulence factors, and others, is 
regulated. For example, the mechanism by Which bacteria 
cause disease involves a delay in the expression of genes 
responsible for formation of virulence factors until the quo 
rum sensing process produces a su?iciently large bacterial 
population that is capable of overWhelming a host’s defense 
system. 
The signaling molecules that are involved in the process of 
quorum sensing are referred to herein as “quorum sensing 
molecules” (QSM). Many gram-negative bacteria use N-acyl 
homoserine lactones as their QSMs, While many gram-posi 
tive bacteria employ oligopeptides. Additionally, a family of 
autoinducers, knoWn as autoinducer-2 (AI-2), can function as 
QSMs and are produced by both gram-positive and gram 
negative bacteria. 
Given the role of the OS process and QSMs in bacterial 
cell-to-cell communication, as Well as the role of this phe 
nomenon in the pathogenesis of many bacteria-related con 
ditions, information about the timing and level of expression 
of QSMs in bacteria-related conditions is desirable to obtain. 
Systems and methods capable of identifying the presence of 
and quantitating QSMs in a particular bacteria-related condi 
tion of interest can provide information useful for under 
standing hoW each bacteria-related condition evolves and is 
maintained. Such understanding can prove useful in the diag 
nosis and characterization of a number of bacteria-related 
conditions and can alloW these conditions to be diagnosed 
and/or monitored such that a treatment can be selected or 
modi?ed depending on the amount of QSMs in a biological 
sample from a subject. 
The presently-disclosed subject matter includes systems, 
methods, and kits for diagnosing and/or monitoring a bacte 
ria-related condition of interest in a subject. The term “bac 
teria-related condition” is used herein to refer to conditions 
Whose symptoms are caused directly or indirectly by the 
invasion and/ or coloniZation of bacteria. For example, in 
some embodiments of the presently-disclosed subject matter, 
the bacteria-related condition can be a bacterial infection, an 
acute or chronic in?ammation, a condition of the gastro 
intestinal tract, or an in?ammatory boWel disease (IBD), such 
as Crohn’s disease (CD) or ulcerative colitis (UC). 
In some embodiments, a method of detecting and/or moni 
toring a bacteria-related condition is provided, Which can lead 
to diagnosis of the condition. In some embodiments, the 
method includes: providing a biological sample from the 
subject; determining an amount in the sample of at least one 
QSM; comparing the amount of the at least one QSM in the 
sample, if present, to a control level of the at least one QSM, 
Wherein the subject is diagnosed as having the bacteria-re 
lated condition of interest or a risk thereof if there is a mea 
surable difference in the amount of the at least one QSM in the 
sample as compared to the control level. 
The term “biological sample” as used herein refers to a 
sample capable of comprising a QSM, Which is derived from 
a subject. The biological sample can be utiliZed for the detec 
tion of the presence and/or level of a QSM of interest in the 
sample. Exemplary biological ?uids include, but are not lim 
ited to, saliva, stool, sputum, blood, plasma, serum, and urine. 
US 8,663,927 B2 
7 
In some embodiments, the biological sample comprises 
saliva. In some embodiments, the sample comprises stool. 
In some embodiments, the QSM is selected from the 
groups consisting of: N-acyl homoserine lactone (AHL) and 
autoinducer-2 (AI-2). It is appreciated that the family of 
QSMs knoWn as AI-2 includes a number of QSMs that inter 
convert into each other and are capable of existing in equilib 
rium in solution. [22] Further, many different types of AHLs 
have been reported in the literature. In some embodiments of 
the presently-disclosed subject matter, the AHL is selected 
from: N-butyryl homoserine lactone (C4-HSL), N-hexanoyl 
homoserine lactone (C6-HSL), N-(3-oxo)-hexanoyl 
homoserine lactone (3-oxo-C6-HSL), N-octanoyl 
homoserine lactone (C8-HSL), N-(3-oxo)-octanoyl 
homoserine lactone (3-oxo-C8-HSL), N-decanoyl 
homoserine lactone (ClO-HSL), N-dodecanoyl homoserine 
lactone (Cl2-HSL), N-(3-oxo)-dodecanoyl homoserine lac 
tone (3-oxo -C l 2-HSL), N-tetradecanoyl homoserine lactone 
(Cl4-HSL), and combinations thereof. 
The terms “diagnosing” and “diagnosis” as used herein 
refer to methods by Which the skilled artisan can estimate and 
even determine Whether or not a subject is suffering from a 
given bacteria-related condition. The skilled artisan often 
makes a diagnosis on the basis of one or more diagnostic 
indicators. The presently-disclosed subject matter provides 
for the measurement of one or more QSMs as diagnostic 
indicators, the amount (including presence or absence) of 
Which is indicative of the presence, severity, or absence of a 
bacteria-related condition. 
Along With diagnosis, clinical prognosis is also an area of 
great concern and interest. It is important to knoW the aggres 
siveness of particular bacteria-related conditions and the like 
lihood of remissions and/or exacerbations in order to plan the 
most effective therapy. Crohn’s disease, for example, is man 
aged by several alternative strategies. In some cases, antibi 
otic therapy may be successfully utiliZed, While, in other 
cases, anti-in?ammatory, steroid, or antibody therapies, or 
combinations thereof, are employed. If a more accurate prog 
no sis can be made, appropriate therapy, and in some instances 
less severe therapy for the subject can be chosen. Measure 
ment of one or more QSMs can be useful in order to separate 
subjects With good prognosis, Who Will need no further 
therapy, from those more likely to have recurring symptoms 
or exacerbations, Who might bene?t from more intensive 
treatments. 
As such, “making a diagnosis” or “diagnosing”, as used 
herein, is further inclusive of making a prognosis, Which can 
provide for predicting a clinical outcome (With or Without 
medical treatment), selecting an appropriate treatment (or 
Whether treatment Would be effective), or monitoring a cur 
rent treatment and potentially changing the treatment, based 
on the measure of QSMs present in a sample. As such, in some 
embodiments, a method of diagnosing a bacteria-related con 
dition is provided that further comprises selecting or modi 
fying a treatment for the bacteria-related condition that is 
based on the determined amount of the at least one QSM. 
Further, in some embodiments of the presently-disclosed sub 
ject matter, multiple determinations of the amounts of QSMs 
over time can be made to facilitate diagnosis and/or progno 
sis. A temporal change in the amount of QSMs can be used to 
predict a clinical outcome, monitor the progression of the 
bacteria-related condition and/or e?icacy of appropriate 
therapies directed against the bacteria-related condition of 
interest. In such an embodiment, for example, one might 
expect to see a decrease in the amount of QSMs in a biological 
sample over time during the course of effective therapy. 
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The presently-disclosed subject matter further provides, in 
some embodiments, a method for determining Whether to 
initiate or continue prophylaxis or treatment of a bacteria 
related condition of interest in a subject. In some embodi 
ments, the method comprises providing a series of biological 
samples over a time period from the subject; analyZing the 
series of biological samples to determine an amount of at least 
one QSM in each of the biological samples; and comparing 
any measurable change in the amounts of the at least one 
QSM in each of the biological samples. Any changes in the 
amounts of the at least one QSM over the time period can be 
used to predict clinical outcome, determine Whether to initiate 
or continue the prophylaxis or therapy of the bacteria-related 
condition, and Whether a current therapy is effectively treat 
ing the bacteria-related condition. For example, a ?rst time 
point can be selected prior to initiation of a treatment and a 
second time point can be selected at some time after initiation 
of the treatment. QSM levels can be measured in each of the 
samples taken from different time points and qualitative and/ 
or quantitative differences noted. A change in the amounts of 
the QSM levels from the ?rst and second samples can be 
correlated With prognosis, determining treatment ef?cacy, 
and/or progression of the disease in the subject. 
The terms “correlated” and “correlating,” as used herein in 
reference to the use of diagnostic and/ or prognostic biomar 
kers, such as QSMs, refers to comparing the presence or 
quantity of the QSM in a subject to its presence or quantity in 
subjects knoWn to suffer from, or knoWn to be at risk of, a 
given condition (e.g., Crohn’s disease); or in subjects knoWn 
to be free of a given condition, i.e. “normal subjects” or 
“control subjects”. For example, a level of a QSM in a bio 
logical sample can be compared to a QSM level determined to 
be associated With a speci?c type of bacteria-related condi 
tion. The sample’s QSM level is said to have been correlated 
With a diagnosis; that is, the skilled artisan can use the QSM 
level to determine Whether the subject suffers from a speci?c 
type of bacteria-related condition, and respond accordingly. 
Alternatively, the sample’s QSM level can be compared to a 
control QSM level knoWn to be associated With a good out 
come (e. g., the absence of a bacteria-related condition), such 
as an average level found in a population of normal subjects. 
In certain embodiments, a diagnostic or prognostic biom 
arker is correlated to a condition or disease by merely its 
presence or absence. In other embodiments, a threshold level 
of a diagnostic or prognostic biomarker can be established, 
and the level of the indicator in a subject sample can simply be 
compared to the threshold level. 
As noted, in some embodiments, multiple determinations 
of one or more diagnostic or prognostic biomarkers can be 
made, and a temporal change in the marker can be used to 
determine a diagnosis or prognosis. For example, a diagnostic 
marker can be determined at an initial time, and again at a 
second time. In such embodiments, an increase in the marker 
from the initial time to the second time can be diagnostic of a 
particular type or severity of bacteria-related condition, or a 
given prognosis. LikeWise, a decrease in the marker from the 
initial time to the second time can be indicative of a particular 
type or severity of bacteria-related condition, or a given prog 
nosis. Furthermore, the degree of change of one or more 
markers can be related to the severity of the bacteria-related 
condition and future adverse events. 
The phrase “determining an amount,” and grammatical 
variations thereof, When used herein in reference to a QSM, 
refers to a qualitative (e. g., present or not present in the 
measured sample), quantitative (e.g., hoW much is present), 
or both, measurement of a QSM. The “control level” is an 
amount (including the qualitative presence or absence) or 









